Extended letermovir prophylaxis for cytomegalovirus in intermediate-risk (R+) kidney transplant recipients: A pilot real-world cohort study (TTS 2026) - Sep 17, 2026 - Abstract #P1.104; Pres time: Sep 21, 2026; 04:45 PM - 06:00 PM; Location: Hall 1-2; P1; "While valganciclovir has been widely used for prophylaxis, its myelotoxicity and potential drug-related adverse events may limit long-term administration...Maintenance immunosuppression consisted of tacrolimus (Tac) plus everolimus (EVR) in 21 patients and Tac plus mycophenolate mofetil (MMF) in 2 patients...One patient experienced diarrhea attributed to tacrolimus, leading to temporary interruption of letermovir; after conversion from Tac to cyclosporine, letermovir was successfully resumed without further complications... In this pilot real-world cohort of CMV R+ kidney transplant recipients, letermovir prophylaxis initiated early after transplantation and continued for approximately 200 days was safe and effective. No CMV DNAemia or acute rejection episodes occurred during prophylaxis, and hematologic toxicity was absent. Our findings suggest that letermovir may represent a viable prophylactic strategy in intermediate-risk (R+) kidney transplant recipients,..."
Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Leukopenia • Neutropenia • Transplant Rejection • Transplantation
|
|
Junji Uchida1; Shunji Nishide1; Yuji Takeyama1; Taiyo Otoshi1; Minoru Kato1; Takeshi Yamasaki1; Tomoaki Iwai1; Toshihide Naganuma1; Katsuyuki Kuratsukuri1
|